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Stroke prevention is central to the management of atrial fibrillation (AF), and 
effective thromboprophylaxis requires oral anticoagulation (OAC).  Even a single 
stroke risk factor confers excess risk, and the net clinical benefit of treatment is 
positive for OAC compared to no treatment or aspirin, whilst aspirin confers a 
neutral or negative NCB1. 
 
Whilst AF patients are at higher intrinsic risk of bleeding2, the use of OAC or aspirin 
increases risk, with intracranial haemorrhage (ICH) being the most serious form of 
bleeding related to antithrombotic therapy3.  The risks of ICH are similar with vitamin 
K antagonists (VKA, e.g., warfarin) and aspirin, especially in the elderly4.  The non-
VKA OACs (NOACs) confer significantly lower risk of ICH compared to VKA5. 
  
Bleeding risk assessment is not a new phenomenon.  For many years, clinicians  used 
‘clinical assessment’, where the presence of, for example, uncontrolled 
hypertension, concomitant NSAID use, alcohol excess, etc.,- was used to estimate (or 
guess) a patient’s bleeding risk. More recently, bleeding risk stratification scores 
incorporating some of the factors associated with excess bleeding have also been 
proposed, but until recently, have had limited uptake in the management of AF 
patients due to their complexity or being non-AF specific. 
 
In 2010, the HAS-BLED score was proposed6 which incorporated the more common 
bleeding risk factors in AF patients, and has since been recommended by guidelines.   
 
Importantly, HAS-BLED draws attention to the reversible bleeding risk factors (e.g., 
uncontrolled hypertension (H), labile INRs (L), concomitant use of NSAIDs or excess 
alcohol (D), etc.) to be addressed by the responsible clinician during the follow-up.  
Risk is not static, and particularly for bleeding, many risk factors can be modified.  
Whilst stroke and bleeding risks track each other, it has been conclusively shown 
that the HAS-BLED score outperforms stroke scores such as CHADS2 or CHA2DS2-VASc 
in predicting bleeding7.  High risk of bleeding (e.g., HAS-BLED score ≥3) is not a 
reason to withhold OAC, instead such patients should be ‘flagged-up’ for more 
careful review and follow-up8.   This is increasingly important in an era of electronic 
health records with ‘electronic alerts’ that identify patients requiring review.  
 
HAS-BLED has also been shown to be predictive of serious bleeding in OAC (whether 
a VKA or non-VKA type), aspirin or no antithrombotic therapy [thus, applicable for 
the full spectrum of AF patients], and in AF and non-AF populations.   HAS-BLED is 
also the only bleeding risk score shown to be predictive of ICH.  
 
Other bleeding risk scores have been proposed for AF patients, such as the ATRIA 
and ORBIT scores, and more recently the ABC-bleeding score9-11. All these scores 
focus on identifying ‘high risk’ patients and some have added complexity by 
weighted scoring (ATRIA9) or including biomarkers (ABC11), or opted for even greater 
simplicity and supposed applicability to any OAC, whether VKA or NOAC (ORBIT10).   
Whilst some of the validation studies imply improved prediction (at least 
statistically) compared to other scores (including HAS-BLED), the crucial question for 
everyday clinical use is the simplicity and practical applicability of these new scores. 
 
In this issue of the Journal of Thrombosis and Haemostasis, Focks et al12 compare the 
performance of the HAS-BLED, ATRIA and HEMORR2HAGES for major bleeding in a 
random sample (N=1,157) of VKA-anticoagulated AF-patients ≥80 years.  They report 
a statistically significant association for these 3 scores with major bleeding, but poor 
predictive ability (C-statistics <0.60). Only two (anaemia, antiplatelet therapy) of the 
classical risk factors were associated with bleeding. Of note, use of the ATRIA 
bleeding score categorized approximately 60% of this cohort as ‘low risk’. 
These findings are highly relevant to the on-going use (and misuse) of bleeding risk 
scores.  As highlighted above, bleeding risk scores are increasingly used to ‘flag up’ 
those patients at high risk for bleeding for review and risk scores that 
inappropriately categorise patients as ‘low risk’ may mean that such patients are 
ignored or have no action taken.   
Also, the focus on the identification of ‘high risk’ patients who actually sustain events 
neglects one of the fundamental purposes of bleeding risk assessment, drawing 
attention to, and correcting, the reversible risk factors.  For easy use in a busy clinic 
or ward, practical scores require inclusion of routinely recorded clinical factors.  
However, any risk scores based on clinical factors have only a modest predictive 
value for predicting high risk patients who will sustain events.  Addition of any 
biomarker – whether blood, urine or imaging based – would clearly improve th 
epredictive value of a clinical score, although the treating clinician would have to 
wait for the results of the biomarker test(s)13.   
Addition of a biomarker to improve risk prediction is not a new concept14.  More 
recent validation studies have used biomarkers in highly selected anticoagulated 
clinical trial cohorts and have demonstrated modest, yet statistically significant 
predictive improvement over the risk scores based on clinical factors alone15. Also, 
many biomarkers have important inter-laboratory and inter-assay variability, as well 
as diurnal and temporal variation which need to be considered.  
As shown recently, adding 'labile INR' (TTR < 65%) to the ORBIT, ATRIA and 
HEMORR2HAGES scores significantly improved their reclassification and 
discriminatory performances for major bleeding whilst on VKA, suggesting that these 
scores may perform sub-optimally in identifying serious bleeding risk in a patient on 
warfarin, unless they were re-calibrated taking labile INRs (or TTRs) into 
consideration16, 17.  In contrast, HAS-BLED categorised adjudicated major bleeding 
events in low-risk and high-risk patients appropriately, whilst ORBIT and ATRIA 
classified most major bleeds into their 'low-risk' categories16.   
Another clear misuse of bleeding risk scores is as an excuse to withhold OAC. Focks 
et al12 clearly show a favorable trade-off for OAC in this elderly cohort, consistent 
with the broad literature showing that the NCB is even greater among the elderly, 
since in most cases, the magnitude of gain from stroke prevention far outweighs the 
smaller risk of serious bleeding even at high HAS-BLED scores18.   
Bleeding risk scores should thus be applied appropriately and not misused [FIGURE].  
The continued preoccupation with trying to improve prediction of ‘high risk’ patients 
with ever more complex scores and (often multiple biomarkers) with only marginal 
improvement in predictive performance, at the cost of simplicity and practically, 
would seem counterintuitive for everyday clinical management.  Risk is also a 
continuum, and patients often do not fall neatly into 3 artificially defined (i.e. low, 
moderate and high) risk categories.  Risk is also not static ‘one-off’ assessment, and 
since AF patients are often elderly with multiple comorbidities, risk assessment has 
to be dynamic with regular review and reassessment – with particular attention to 
reversible risk factors, whether for bleeding or stroke.  
The continued misuse of these scores will ultimately be to the detriment of AF 
patient management, and greater awareness and understanding of appropriate 
practical use is needed.  Ultimately, patients place greater value on stroke 
prevention, and even to avoid one stroke (regarded by some as a fate worse than 
death) patients may be prepared to sustain 4 major bleeds19, 20.  Surely we can do 
better. 
 
   
 
  
  
FIGURE 1 
Appropriate use of bleeding risk assessment in patients with atrial fibrillation 
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